Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
52 hedge funds and large institutions have $61.7M invested in Enzo Biochem, Inc. in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 10 closing their positions.
151% more capital invested
Capital invested by funds: $24.5M → $61.7M (+$37.2M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
6% more call options, than puts
Call options by funds: $674K | Put options by funds: $638K
0% more funds holding
Funds holding: 52 → 52 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
63% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.42M |
| 2 |
PCM
Potomac Capital Management
New York
|
+$314K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$113K |
| 4 |
Millennium Management
New York
|
+$105K |
| 5 |
FLC
Fifth Lane Capital
Austin,
Texas
|
+$81.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$1.82M |
| 2 |
Morgan Stanley
New York
|
-$292K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$138K |
| 4 |
SFG
SNS Financial Group
Minneapolis,
Minnesota
|
-$89.4K |
| 5 |
Renaissance Technologies
New York
|
-$65.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FWM
51
Focused Wealth Management
Newburgh,
New York
| $267 | – | – | – |
|
|
NA
52
NewEdge Advisors
New Orleans,
Louisiana
| $24 | – | – | – |
|
|
SFG
53
SNS Financial Group
Minneapolis,
Minnesota
| – | -$89.4K | -62,500 | Closed |
|
54
Belvedere Trading
Chicago,
Illinois
| – | -$50.5K | -35,350 | Closed |
|
55
Group One Trading
Chicago,
Illinois
| – | -$41.6K | -27,996 | Closed |
|
56
Wolverine Trading
Chicago,
Illinois
| – | -$31.6K | -21,266 | Closed |
|
57
Prudential Financial
Newark,
New Jersey
| – | -$26K | -18,200 | Closed |
|
|
APIM
58
Agate Pass Investment Management
Bainbridge Island,
Washington
| – | -$23.3K | -16,292 | Closed |
|
59
UBS Group
Zurich,
Switzerland
| – | -$1.94K | -1,353 | Closed |
|
|
CA
60
Corrado Advisors
Ramsey,
New Jersey
| – | -$786 | -550 | Closed |
|
61
Fidelity Investments
Boston,
Massachusetts
| – | -$741 | -518 | Closed |
|
62
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$189 | -132 | Closed |
|
ENZ Hedge Fund Activity: Q1 2023 in Review
52 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q1 2023, worth a combined $61.7M — up 151% from $24.5M a quarter earlier.
Fund positioning in ENZ was balanced in Q1 2023: 10 funds opened new positions, 10 closed out, 6 added to existing stakes and 16 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $3.42M. The largest seller was Roumell Asset Management, cutting an estimated $1.82M.
- 52 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $61.7M of Enzo Biochem, Inc. stock for Q1 2023, up 151% quarter-over-quarter.
- 10 funds opened new Enzo Biochem, Inc. positions in Q1 2023 and 10 closed out, a net change of 0 holders.
- The largest Enzo Biochem, Inc. buyer in Q1 2023 was Tang Capital Management, an estimated $3.42M added.
- The largest Enzo Biochem, Inc. seller in Q1 2023 was Roumell Asset Management, an estimated $1.82M sold.
Based on aggregated 13F filings for Q1 2023.